Kezar Life Sciences, Inc. (KZR)
Stock Price:
$5.74 USD
0.11 (1.95%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
265.51M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-38.24M |
| Shares Out |
46.26M |
| EPS (ttm) |
-1.34 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$5.74 |
| Previous Close |
$5.63 |
| Change ($) |
0.11 |
| Change (%) |
1.95% |
| Day's Open |
5.62 |
| Day's Range |
5.59 - 5.80 |
| Day's Volume |
107,944 |
| 52-Week Range |
2.18 - 9.79 |
More Stats
| Market Cap |
265.51M |
| Enterprise Value |
113.97M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
46.26M |
| Float |
37.72M |
| EPS (basic) |
-1.50 |
| EPS (diluted) |
-1.34 |
| FCF / Share |
-0.79 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.50M |
| Short Ratio |
7.00 |
| Short % of Float |
3.97% |
| Beta |
0.13 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.69 |
| Revenue |
n/a |
| Operating Income |
-40.01M |
| Net Income |
-38.24M |
| Free Cash Flow |
-34.05M |
| Net Cash |
151.54M |
| Net Cash / Share |
3.28 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-18.28% |
| ROE |
-30.24% |
| ROIC |
-36.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$13.00*
(126.48% upside)
Low
8.00
Current: $5.74
High
18.00
Target: 13.00
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -37.34 | -24.73 | -8.75 | -8.99 |
| Net Income | -35.09 | -23.17 | -8.52 | -8.99 |
| Shares Outstanding | 19.08 | 10.26 | 0.60 | 0.34 |
| Earnings Per Share | -1.84 | -2.26 | -14.21 | -26.56 |
| Operating Cash Flow | -29.88 | -20.79 | -8.11 | -9.76 |
| Capital Expenditures | -0.61 | -1.11 | -0.39 | -0.13 |
| Free Cash Flow | -30.48 | -21.90 | -8.50 | -9.89 |
| Cash & Equivalents | 78.21 | 107 | 51.05 | - |
| Total Debt | 6.36 | - | - | - |
| Net Cash / Debt | 71.84 | 107 | 51.05 | - |
| Assets | 89.51 | 115 | 54.22 | - |
| Liabilities | 11.47 | 5.89 | 1.98 | - |
| Book Value | 78.05 | 109 | -25.69 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Kezar Life Sciences, Inc. |
| Country |
United States |
| Employees |
40 |
| CEO |
John Fowler |
Stock Information
| Ticker Symbol |
KZR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KZR |
| IPO Date |
June 21, 2018 |
Description
Kezar Life Sciences, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is headquartered in South San Francisco, California.